$21.54 Million in Sales Expected for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) This Quarter

Brokerages expect that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will post $21.54 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings. The highest sales estimate is $22.77 million and the lowest is $20.20 million. Ultragenyx Pharmaceutical posted sales of $12.79 million during the same quarter last year, which suggests a positive year over year growth rate of 68.4%. The company is expected to issue its next earnings results on Thursday, August 1st.

According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full-year sales of $95.45 million for the current fiscal year, with estimates ranging from $87.10 million to $103.26 million. For the next year, analysts anticipate that the firm will report sales of $197.32 million, with estimates ranging from $142.10 million to $248.64 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.73) by ($0.09). The company had revenue of $18.17 million during the quarter, compared to analyst estimates of $18.75 million. Ultragenyx Pharmaceutical had a negative return on equity of 51.00% and a negative net margin of 550.30%. The business’s revenue for the quarter was up 70.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.63 earnings per share.

A number of equities analysts have recently commented on RARE shares. Barclays reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Thursday, May 9th. ValuEngine downgraded shares of Ultragenyx Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 8th. BidaskClub raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Friday, March 15th. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and set a $73.00 price objective for the company in a report on Tuesday, April 23rd. Finally, Morgan Stanley set a $83.00 price objective on shares of Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a report on Monday, June 17th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $78.56.

In related news, EVP Karah Herdman Parschauer sold 1,489 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $63.01, for a total value of $93,821.89. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders sold 3,183 shares of company stock worth $201,185. Corporate insiders own 7.80% of the company’s stock.

Several hedge funds have recently bought and sold shares of RARE. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Ultragenyx Pharmaceutical by 8.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,113 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 242 shares during the last quarter. American International Group Inc. raised its holdings in Ultragenyx Pharmaceutical by 0.8% during the 4th quarter. American International Group Inc. now owns 31,456 shares of the biopharmaceutical company’s stock worth $1,368,000 after purchasing an additional 265 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in Ultragenyx Pharmaceutical by 16.6% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,924 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 274 shares during the last quarter. Meeder Asset Management Inc. grew its position in shares of Ultragenyx Pharmaceutical by 321.1% during the 1st quarter. Meeder Asset Management Inc. now owns 598 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 456 shares during the period. Finally, First Mercantile Trust Co. grew its position in shares of Ultragenyx Pharmaceutical by 101.0% during the 1st quarter. First Mercantile Trust Co. now owns 985 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 495 shares during the period.

NASDAQ RARE traded up $1.03 during midday trading on Tuesday, hitting $57.39. The company had a trading volume of 288,579 shares, compared to its average volume of 551,605. The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.60 and a current ratio of 11.77. The firm has a market cap of $3.42 billion, a PE ratio of -7.77 and a beta of 2.17. The stock has a fifty day moving average of $59.37. Ultragenyx Pharmaceutical has a fifty-two week low of $37.44 and a fifty-two week high of $90.98.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Read More: Marijuana Stocks

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.